CytomX Therapeutics, Inc. (NASDAQ:CTMX)‘s stock had its “hold” rating reiterated by equities research analysts at Cann in a research note issued on Tuesday.

The analysts wrote, “Loss per share was $0.69, compared to our estimate of $0.56. This was the result of higher than expected R&D expense of $28.1 million compared to our estimate of $15.2 million, which resulted from a $10 million payment to UCSB for a sublicense payment. This was partially offset by higher than estimated revenue of $8.8 million compared to our estimated $1.0 million.””

Several other equities research analysts also recently issued reports on CTMX. Jefferies Group LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of CytomX Therapeutics in a research note on Wednesday, April 26th. Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Wednesday, May 3rd. HC Wainwright reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research note on Monday, May 8th. ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of CytomX Therapeutics in a research note on Wednesday, June 28th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $24.50.

Shares of CytomX Therapeutics (NASDAQ:CTMX) traded up 8.28% during trading on Tuesday, hitting $14.78. 302,806 shares of the company were exchanged. The stock’s market cap is $543.15 million. CytomX Therapeutics has a 12 month low of $9.85 and a 12 month high of $20.02. The company’s 50-day moving average price is $14.69 and its 200 day moving average price is $14.41.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.30. CytomX Therapeutics had a negative return on equity of 59.65% and a negative net margin of 208.92%. The firm had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $4.95 million. On average, equities analysts predict that CytomX Therapeutics will post ($1.41) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Cann Reaffirms Hold Rating for CytomX Therapeutics, Inc. (NASDAQ:CTMX)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/cann-reaffirms-hold-rating-for-cytomx-therapeutics-inc-nasdaqctmx.html.

In other news, insider Sean A. Mccarthy sold 4,781 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $15.52, for a total value of $74,201.12. Following the completion of the sale, the insider now owns 9,026 shares of the company’s stock, valued at approximately $140,083.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $15.47, for a total transaction of $38,675.00. Following the completion of the sale, the chief financial officer now directly owns 22,126 shares of the company’s stock, valued at approximately $342,289.22. The disclosure for this sale can be found here. Insiders sold a total of 32,062 shares of company stock valued at $497,641 in the last three months. Insiders own 8.00% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC bought a new stake in CytomX Therapeutics during the first quarter valued at $313,000. Vident Investment Advisory LLC increased its stake in CytomX Therapeutics by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 75,924 shares of the biotechnology company’s stock valued at $1,311,000 after buying an additional 12,652 shares during the last quarter. Hamilton Lane Advisors LLC bought a new stake in CytomX Therapeutics during the first quarter valued at $366,000. Russell Investments Group Ltd. bought a new stake in CytomX Therapeutics during the fourth quarter valued at $243,000. Finally, Spark Investment Management LLC increased its stake in CytomX Therapeutics by 52.5% in the first quarter. Spark Investment Management LLC now owns 101,700 shares of the biotechnology company’s stock valued at $1,756,000 after buying an additional 35,000 shares during the last quarter. 52.33% of the stock is owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.